Anzeige
Mehr »
Freitag, 31.10.2025 - Börsentäglich über 12.000 News
Attestation ist die Killer-App - Republic baut sie jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRU | ISIN: US30233G2093 | Ticker-Symbol: PV3B
Tradegate
31.10.25 | 09:27
10,465 Euro
-0,85 % -0,090
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
EYEPOINT PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EYEPOINT PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
11,11511,32021:58
10,98011,54521:58

Aktuelle News zur EYEPOINT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiEyePoint Pharmaceuticals, Inc.: EyePoint to Report Third Quarter 2025 Financial Results on November 5, 20255
EYEPOINT PHARMACEUTICALS Aktie jetzt für 0€ handeln
16.10.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)3
15.10.EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study3
15.10.EyePoint prices public offering at $12.00 per share, raises $150M to boost DURAVYU Phase 3 clinical programs2
15.10.EyePoint Pharmaceuticals prices $150 million public offering6
15.10.EyePoint Pharmaceuticals, Inc.: EyePoint Announces Pricing of Public Offering1
14.10.Eyepoint Pharmaceuticals stock falls after $150 million share offering1
14.10.EyePoint Pharmaceuticals launches $150 million public offering3
14.10.EyePoint announces proposed public offering of common stock2
14.10.EyePoint Pharmaceuticals, Inc.: EyePoint Announces Proposed Public Offering of Common Stock1
14.10.EyePoint files automatic mixed securities shelf1
14.10.EyePoint startet Phase-3-Studien für DURAVYU bei diabetischer Augenerkrankung3
14.10.EyePoint's DURAVYU advances to phase 3 trials for diabetic eye disease1
14.10.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
14.10.EyePoint Pharmaceuticals, Inc.: EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU in Diabetic Macular Edema278- DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 - - New preclinical...
► Artikel lesen
02.10.EyePoint stock rating reiterated at Outperform by Mizuho amid competitor review10
29.09.EYEPOINT PHARMA - Sind nochmal 35 % drin?5
16.09.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)205WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
► Artikel lesen
18.08.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)224WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
14.08.Mizuho hebt Kursziel für EyePoint Pharmaceuticals auf 28 US-Dollar an38
Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1